(Q36155804)

PubMed publication ID

27712994

12 August 2017

title

Identification of high-affinity anti-CD16A allotype-independent human antibody domains (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6957250&resulttype=core&format=json

13 May 2020

author name string

Wei Li

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6957250&resulttype=core&format=json

13 May 2020

Hongjia Yang

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6957250&resulttype=core&format=json

13 May 2020

Dimiter S Dimitrov

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6957250&resulttype=core&format=json

13 May 2020

publication date

3 October 2016

1 reference

PubMed publication ID

27712994

Experimental and Molecular Pathology

12 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6957250&resulttype=core&format=json

13 May 2020

volume

101

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6957250&resulttype=core&format=json

13 May 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6957250&resulttype=core&format=json

13 May 2020

page(s)

281-289

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6957250&resulttype=core&format=json

Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells

13 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

ZDOCK: an initial-stage protein-docking algorithm.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

Therapeutic antibodies, vaccines and antibodyomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

Human neutrophil Fc gamma receptor distribution and structure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

Interaction sites on human IgG-Fc for FcgammaR: current models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

On guard--activating NK cell receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

Membrane anchoring and spontaneous release of CD16 (FcR III) by natural killer cells and granulocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

DECOMP: a PDB decomposition tool on the web.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

Combination of the CHARMM27 force field with united-atom lipid force fields

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

A human immunoglobulin G receptor exists in both polypeptide-anchored and phosphatidylinositol-glycan-anchored forms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

Natural killer cells in human autoimmune diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal haemoglobinuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

The Fc gamma receptor of natural killer cells is a phospholipid-linked membrane protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

Soluble monomeric IgG1 Fc.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2016.10.001

Human monocytes and U937 cells bear two distinct Fc receptors for IgG.

7 January 2021

1 reference

12 December 2020

Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype

1 reference

12 December 2020

Different membrane anchors of Fc gamma RIII (CD16) on K/NK-lymphocytes and neutrophils. Protein- vs lipid-anchor.

1 reference

12 December 2020

Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors

1 reference

12 December 2020

Human Fc gamma RIII (CD16). Isoforms with distinct allelic expression, extracellular domains, and membrane linkages on polymorphonuclear and natural killer cells

1 reference

12 December 2020

10.1016/J.YEXMP.2016.10.001

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6957250&resulttype=core&format=json

13 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6957250&resulttype=core&format=json

13 May 2020

PubMed publication ID

27712994

1 reference